Compare Merck & Co., Inc. (MRK) vs Vistra Corp (VST) Price & Performance

Merck & Co., Inc.Trade

Vistra CorpTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Vistra Corp — how do they compare? Merck & Co., Inc. trades at $130.22 (market cap $321.77B), while Vistra Corp trades at $146.13 (market cap $48.64B). The key difference: Merck & Co., Inc. is far larger — about 6.6× Vistra Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

	MRK	VST
Market Cap	$321.77B	$48.64B
Sector	Health	Technology
52-Week High	$131.84	$217.92
52-Week Low	$77.60	$134.71
Enterprise Value	$368.53B	$70.58B
Dividend Yield	2.61%	0.63%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Vistra Corp

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.PRNewsWire · 5 hours agoBullish Trump orders splitting MMR vaccine into three shots despite no scientific support and expert criticism.CNBC · 23 hours agoBearish View details →

VST

Vistra Corp. holds steady as earnings rise but sales fall amid rising costs and strategic growth moves.Seeking Alpha · 4 days agoNeutral Vistra misses Q3 earnings estimates due to $472M hedge loss but core operations show strong 30% EBITDA growth.Gordon Thompson · 4 days agoNeutral View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Vistra Corp

Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.